Yes.Interviews starting in mid- January. Practice the alphabet and counting to 100, and you’ll be prepared for round one.
Check back in 2030...Pfizer may have it figured out by then. You are an optimist! It’s proving to be a different animal, PFE is not exactly a market trailblazer; too big, not flexible and too much reliance on past history in guiding decisions. Just the facts- nimble and flexible are not strong suites.
BioSimilars is strong with several current agents being marketed and several blockbusters coming in 1-2yrs. However BioSimilars the way Pfizer manages it is 100% contract price sell. Most co getting into the space are figuring out you have to sell Biosimilars like a Generic business model w loss looser first few years for mkt share & contracts. Pfizer still is stubborn trying to sell their BioSimilars like a Branded agent against its Branded molecule. Why in world would anybody ever switch a patient from Branded to Biosimilar w zero clinical differences if there is not any major price differences. And when its a Buy & Bill agent then there are so many ways to provide back end discounts & rebates that small prices differences are easily matched or beat The way Pfizer has approached BioSimilars is not the way to be successful. One reason the BioSimilar division has a 50% turnover & all the current reps have there resume on the streets. Most co, BioSimilars is a good opportunity, with Pfizer you need to run away FAST as the company does not know how to sell in a generic type of environment. They have messed up for decades w Greenstone generic opportunities of Lipitor, Celebrex, ect so they have zero clue how to sell in a generic market. Trying to sell BioSimilars as a Branded agent w Branded strategies is beyond comical. Its clueless. BTW BioSimilars cost $20 a unit for Pfizer to make but they are trying to sell it for $500 a unit (at least Inflectra)
